Senseonics Holdings, Inc. · NASDAQ:SENS
Senseonics — Investor Presentation (August 2022)
18 slides from Senseonics's investor presentation, August 2022
Slide 1: Eversense CGM System Corporate Presentation
Eversense ® CGM System The world’s FIRST and ONLY long-term Continuous Glucose Monitoring System Tim Goodnow, PhD Corporate Presentation President and CEO August 2022 1
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Any statements in this presentation about future expectations, plans and prospects for Senseonics, including statements about patient benefits, perceptions, uptake of the Eversense E3 product, and the ability to introduce the product to additional patients, statements rega
Slide 3: Our Mission
OUR MISSION To transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. 3
Slide 4: Corporate Overview and Milestones
CORPORATE OVERVIEW AND MILESTONES The FIRST and ONLY long-term and implantable CGM System. Available by prescription in US and select markets in Europe. Proven technology with rich development history, regulatory approvals and commercial accomplishments. 2016 - 2017 2018 2019 2020 2021 2022 Feb. 1 O
Slide 5: High Growth Market
HIGH GROWTH MARKET CGM Fastest Growing Diabetes Technology Segment Globally* CGM Global Market Size $8.2 ~ 37% CAGR $7.1 $14B+ Revenue in Billions ($) $5.6 Annual US Market $4.3 Opportunity $2.7 $1.7 *Estimates for top 4 CGM companies (Dexcom, Abbott, Medtronic and Senseonics), based upon available
Slide 6: Significant Unmet Need Among BGM/CGM Users
SIGNIFICANT UNMET NEED AMONG BGM/CGM USERS Why BGM users won't adopt CGM1 Most desired CGM improvements 2 Longer Sensor Wear Better Accuracy Dexcom Medtronic Abbott 1 Market Segmentation Research June 2019 dQ&A CGM US Patient Survey Q3 2020 2 dQ&A CGM US Patient Survey Q3 2020 6
Slide 7: Eversense CGM System addresses unmet needs as the first and only
Eversense CGM System addresses unmet needs as THE FIRST AND ONLY ▪ CGM that lasts for 6 months vs. days ▪ Fully implantable 3rd generation sensor ▪ CGM achieves 8.5% MARD ▪ Transmitter that is removable ▪ System with on-body vibe alerts for hypo and hyper warnings ▪ System with fresh, gentle-on skin
Slide 8: Eversense US Patient Profiles
1 EVERSENSE US PATIENT PROFILES Broad appeal of Eversense with new and existing CGM users Target patient profiles Where Eversense users Usage split evenly Users by come from across age groups Diabetes Type ▪ Dissatisfied with Current CGM ▪ New to CGM 22% 29% 20% 21% 20% Market Expansion/ 19% ▪ Gatew
Slide 9: Proven Top-Tier Accuracy in PROMISE Study
1 PROVEN TOP-TIER ACCURACY IN PROMISE STUDY MARD: 8.5% Exceptional Performance for Duration of 180 Days ▪ Prospective multi-center pivotal trial Accurate and stable for 6 months Highly accurate – at 8 sites in the US for new 180-day Percent of readings within 15 mg/dL or 15% of particularly in low r
Slide 10: Strong and Expanding Reimbursement
STRONG AND EXPANDING REIMBURSEMENT ▪ Recent Anthem coverage decision, expands access to over 250 million lives ▪ Strong adoption of 180-day payment across Commercial payers ▪ CMS issued G-codes, effective July 1st – providing Medicare beneficiaries access to 180-day product 10
Slide 11: Commercial Collaboration with Ascensia
COMMERCIAL COLLABORATION WITH ASCENSIA ▪ Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in BGM ▪ ASCENSIA is the Exclusive Worldwide Distribution Partner for Eversense®, Eversense® XL, Eversense® E3 and Future Generation Products ▪ Senseonics to Focus Stre
Slide 12: Eversense Pipeline
EVERSENSE PIPELINE 12
Slide 13: Product Vision
PRODUCT VISION Uniquely differentiated long-term technology solution with multiple product configurations SENSOR All Diabetes Patient Segments NO sensor change for 1 year NO daily calibration required NO transmitter on body For Type 1 and Type 2 Patients On Demand and Continuous Monitoring NOTE: Pro
Slide 14: Senseonics Product Pipeline
SENSEONICS PRODUCT PIPELINE 2016 - 2022 2022 - 2025 Eversense CGM 180D CGM BGM Connectivity 365D CGM (Rome) 90-day CGM system 6-month sensor with Direct communication with One year sensor for advanced chemistry Bluetooth enabled blood continuous readings, 1 cal/week Eversense XL CGM and features g
Slide 15: Eversense 365 System
EVERSENSE 365 SYSTEM One annual sensor for use – CGM for peace of mind and FGM for discretion TECHNOLOGY Gen 2 sensor (Rome); array-based sensing USE CASE Full year use with 1 sensor and 1 cal/week TARGET Intensively managed patients who want better control + All insulin-using patients NOTE: Timelin
Slide 16: Freedom System
FREEDOM SYSTEM Autonomous sensor testing with data processing capacity enabling 2 products from 1 platform TECHNOLOGY Enhanced Rome 2 sensor with integrated battery; updated algorithm USE CASE Full year use with 1 sensor and 1 cal/week Two unique products: 1. CGM with transmitter/FGM without transmi
Slide 17: Eversense Continuous Glucose Monitoring System
ae “e\/ersense. Continuous Glucose Monitoring System “ACCURATE. CONVENIENT. LIFE-CHANGIN e€Versense. Continuous Glucose Monitoring System 17
Slide 18: Thank You
THANK YOU 18
Senseonics Holdings — Investor Presentation (August 2022) on 6ix